Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible

Orthodontics and Craniofacial Research

Volumn 13, Issue 4, 2010, Pages 214-222

  Kubek, D J ^a   Burr, D B ^a,b,c   Allen, M R ^a  

^a UNIVERSITY OF INDIANAPOLIS   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Indiana University Purdue University Indianapolis   (United States)

Author keywords

BRONJ; Jaw necrosis; Osteonecrosis; Osteonecrosis of the jaw; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CALCEIN; COLORING AGENT; DIAGNOSTIC AGENT; DRUG VEHICLE; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; FUCHSINE; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ANIMAL; ARTICLE; BONE DEVELOPMENT; BONE MATRIX; BONE MINERALIZATION; BONE REMODELING; C3H MOUSE; COMPARATIVE STUDY; DENTIN; DRUG EFFECT; FEMALE; FEMUR; HAVERSIAN CANAL; JAW; MANDIBLE; MOUSE; NECROSIS; OVARIECTOMY; PATHOLOGY; PERIODONTAL LIGAMENT; TOOTH DEVELOPMENT;

ALVEOLAR PROCESS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MATRIX; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; COLORING AGENTS; DENTIN; DIPHOSPHONATES; FEMALE; FEMUR; FLUORESCEINS; FLUORESCENT DYES; HAVERSIAN SYSTEM; IMIDAZOLES; MANDIBLE; MICE; MICE, INBRED C3H; NECROSIS; OSTEOGENESIS; OVARIECTOMY; PERIODONTAL LIGAMENT; PHARMACEUTICAL VEHICLES; ROSANILINE DYES; TOOTH CALCIFICATION;

EID: 77958098046     PISSN: 16016335     EISSN: 16016343     Source Type: Journal    
DOI: 10.1111/j.1601-6343.2010.01497.x     Document Type: Article

References (35)

1. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
3. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.
4. Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med 2009;60:85-96.
5. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009;67:61-70.
6. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008;66:987-94.
7. Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 2010;25:98-105.
8. Jowsey J. Studies of Haversian systems in man and some animals. J Anat 1966;100:857-64.
9. Li CY, Schaffler MB, Wolde-Semait HT, Hernandez CJ, Jepsen KJ. Genetic background influences cortical bone response to ovariectomy. J Bone Miner Res 2005;20:2150-8.
10. Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006;39:872-9.
11. Foldes J, Shih MS, Parfitt AM. Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res 1990;5:1063-7.
12. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ et al. Bone histomorphometry - standardization of nomenclature, symbols, and units. J Bone Miner Res 1987;2:595-610.
13. Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res. 2010:25:1668-79.
14. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 2009;45:164-72.
15. Biasotto M, Chiandussi S, Zacchigna S, Moimas S, Dore F, Pozzato G et al. A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw. J Oral Pathol Med 2010;39:390-6.
16. Hokugo A, Christensen R, Chung E, Sung E, Felsenfeld AL, Sayre JW et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 2010;25:1337-49.
17. Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab 2009;27:663-72.
18. Senel FC, Duman MK, Muci E, Cankaya M, Pampu AA, Ersoz S et al. Jaw bone changes in rats after treatment with zoledronate and pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:385-91.
19. Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab 2010;28:165-75.
20. Gotcher JE, Jee WS. The progress of the periodontal syndrome in the rice rat. II. The effects of a diphosphonate on the periodontium. J Periodontal Res 1981;16:441-55.
21. Allen MR, Chu TG, Kubek D, Burr DB. Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs. Osteoporos Int 2010; doi: 10.1007/s00198-010-1268-4 (Epub ahead of print).
22. Burr DB, Allen MR. Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofac Res 2009;12:221-8.
23. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2010;68:959-63.
24. Allen MR. Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact 2007;7:358-60.
25. Allen MR. Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells: Tissues Organs 2009;189:289-94.
26. Meta IF, Fernandez SA, Gulati P, Huja SS. Alveolar process anabolic activity in C3H/HeJ and C57BL/6J inbred mice. J Periodontol 2008;79:1255-62.
27. Borah B, Dufresne T, Nurre J, Phipps R, Chmielewski P, Wagner L et al. Risedronate reduces intracortical porosity in women with osteoporosis. J Bone Miner Res 2010;25:41-7.
28. Smith SY, Recker RR, Hannan M, Muller R, Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003;32:45-55.
29. Baumann BD, Wronski TJ. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 1995;16:247-53.
30. Melsen B. Tissue reaction to orthodontic tooth movement - a new paradigm. Eur J Orthod 2001;23:671-81.
31. Feher A, Koivunemi A, Koivunemi M, Fuchs RK, Burr DB, Phipps RJ et al. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone 2010;46:203-7.
32. Huja SS, Fernandez SA, Phillips C, Li Y. Zoledronic acid decreases bone formation without causing osteocyte death in mice. Arch Oral Biol 2009;54:851-6.
33. Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 2008;82:354-60.
34. Enlow DH. Osteocyte necrosis in normal bone. J Dent Res 1966;45:213.
35. Frost HM. Micropetrosis J Bone Joint Surg Am 1960;42-A:144-50.